A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan
NCT ID: NCT02343250
Last Updated: 2016-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
54 participants
INTERVENTIONAL
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan
NCT02088008
A Drug Interaction Study of Cilnidipine and Valsartan
NCT01838967
Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension
NCT02145104
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
NCT02368652
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy
NCT02368665
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cinidipine/Valsartan tablet
Cinidipine/Valsartan tablet
Cilnidipine/Valsartan
Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
Cilnidipine+Valsartan
Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
Cilnidipine+Valsartan
coadministration of cilinidipine and valsartan
Cilnidipine+Valsartan
Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
Cilnidipine/Valsartan
Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cilnidipine/Valsartan
Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
Cilnidipine+Valsartan
Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
Cilnidipine/Valsartan
Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
Cilnidipine+Valsartan
Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent
Exclusion Criteria
* Hypertension of hypotension
19 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IlDong Pharmaceutical Co Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyungsang Yu, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID-IDCV-103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.